UroGen Pharma Ltd.

LSE:0XOD Stock Report

Market Cap: US$464.6m

UroGen Pharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Liz Barrett

Chief executive officer

US$4.6m

Total compensation

CEO salary percentage17.1%
CEO tenure6yrs
CEO ownership0.8%
Management average tenure4.4yrs
Board average tenure6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Liz Barrett's remuneration changed compared to UroGen Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$115m

Jun 30 2024n/an/a

-US$114m

Mar 31 2024n/an/a

-US$104m

Dec 31 2023US$5mUS$794k

-US$102m

Sep 30 2023n/an/a

-US$105m

Jun 30 2023n/an/a

-US$109m

Mar 31 2023n/an/a

-US$112m

Dec 31 2022US$2mUS$764k

-US$110m

Sep 30 2022n/an/a

-US$109m

Jun 30 2022n/an/a

-US$114m

Mar 31 2022n/an/a

-US$113m

Dec 31 2021US$4mUS$739k

-US$111m

Sep 30 2021n/an/a

-US$113m

Jun 30 2021n/an/a

-US$111m

Mar 31 2021n/an/a

-US$117m

Dec 31 2020US$2mUS$637k

-US$128m

Sep 30 2020n/an/a

-US$137m

Jun 30 2020n/an/a

-US$130m

Mar 31 2020n/an/a

-US$121m

Dec 31 2019US$26mUS$695k

-US$105m

Compensation vs Market: Liz's total compensation ($USD4.64M) is above average for companies of similar size in the UK market ($USD970.93K).

Compensation vs Earnings: Liz's compensation has increased whilst the company is unprofitable.

CEO

Liz Barrett (62 yo)

6yrs

Tenure

US$4,639,589

Compensation

Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She has been a Director at Allogene Therapeutics, Inc. sin...

Leadership Team

NamePositionTenureCompensationOwnership
Elizabeth Barrett
President6yrsUS$4.64m0.77%
$ 3.6m
Jason Smith
General Counsel4.4yrsUS$1.51m0.060%
$ 277.7k
Mark Schoenberg
Chief Medical Officer7.1yrsUS$1.36m0.34%
$ 1.6m
Christopher Degnan
Chief Financial Officerless than a yearno datano data
Vincent Perrone
Senior Director of Investor Relationsno datano datano data
Bryon Wornson
Executive Vice President of Talent1.4yrsno datano data
Marina Konorty
Executive Vice President of Research & Development and Technical Operations4.8yrsno datano data
James Ottinger
Executive Vice President of Regulatory Affairs & Quality4.8yrsno datano data
Polly Murphy
Chief Business Officer4.3yrsno datano data
Michael Louie
Senior Vice President of Medical Affairs & Clinical Development1.4yrsno datano data
David Lin
Chief Commercial Officerless than a yearno datano data
Gil Hakim
Consultant6.4yrsUS$3.86mno data

4.4yrs

Average Tenure

56.5yo

Average Age

Experienced Management: 0XOD's management team is considered experienced (4.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Elizabeth Barrett
President6yrsUS$4.64m0.77%
$ 3.6m
Cynthia Butitta
Independent Director7.3yrsUS$204.06k0%
$ 0
Stuart Holden
Independent Director9.1yrsUS$201.53k0%
$ 0
Arie Belldegrun
Independent Chairman12.1yrsUS$342.18k0.97%
$ 4.5m
Daniel Wildman
Independent Director2.2yrsUS$192.72k0%
$ 0
Jack Baniel
Member of Scientific Advisory Boardno datano datano data
Herbert Lepor
Chairman of Scientific Advisory Boardno datano datano data
Fred Witjes
Member of Scientific Advisory Boardno datano datano data
James Robinson
Independent Director1.5yrsUS$313.29k0%
$ 0
Leana Wen
Independent Director2.4yrsUS$194.41k0%
$ 0

6.0yrs

Average Tenure

67yo

Average Age

Experienced Board: 0XOD's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 03:07
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

UroGen Pharma Ltd. is covered by 18 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anita DushyanthBerenberg
Jonathan AschoffB. Riley Wealth
Jason KolbertD. Boral Capital LLC.